Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropivacaine delivery after gastrointestinal resectional surgery
ACTRN12613000380796Phase 3Completed
- Sponsor
- Hunter New England Local Health District
- Start
- Apr 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ropivacaine in postoperative pain (2 arms), sponsored by Hunter New England Local Health District. Primary endpoint: Change in pulmonary function. Started Apr 2013; status: completed.
02
Drugs
ropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ACTRN12613000380796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000380796.